TOWARD AN EPIDEMIOLOGY AND NATURAL-HISTORY OF SIRS (SYSTEMIC INFLAMMATORY RESPONSE SYNDROME)

被引:379
作者
BONE, RC [1 ]
机构
[1] RUSH MED COLL,CHICAGO,IL 60612
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1992年 / 268卷 / 24期
关键词
D O I
10.1001/jama.268.24.3452
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background.-New definitions for sepsis and the systemic inflammatory response syndrome (SIRS) have been established. Comparatively little is known, however, about the types of patients who will be included within these new definitions. Objectives.-To determine what is and what is not-known about the epidemiology and natural history of severe sepsis and SIRS. Design.-A comparative analysis of patient characteristics in the Methylprednisolone, Veterans Administration Systemic Sepsis, HA-1A, and E5 studies. Results.-At least 15% of patients in these studies had no documented infection; the proportion of all patients with severe SIRS and no documented infection is probably higher. Even among patients with presumed infection, less than half had bacteremia, and only about half had gram-negative infection or shock. The difference in the mean mortality rate of the combined studies at 14 days was 26%, while at 1 month it was 42%. Gram-negative sepsis and gram-positive sepsis seem to have similar mortality rates. Whether shock increases 30-day mortality is unclear. Conclusions.-Patients with severe SIRS should not be assumed to have gram-negative infection; furthermore, data derived from studies of patients with gram-negative infection should be applied cautiously to all patients with SIRS. Studies of patients with sepsis or SIRS should include at least a 1-month follow-up if mortality is an end point. More consistent definitions of these disorders should permit more effective comparisons across studies.
引用
收藏
页码:3452 / 3455
页数:4
相关论文
共 13 条
  • [1] THE PATHOGENESIS OF SEPSIS
    BONE, RC
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) : 457 - 469
  • [2] A CRITICAL-EVALUATION OF NEW AGENTS FOR THE TREATMENT OF SEPSIS
    BONE, RC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (12): : 1686 - 1691
  • [3] A CONTROLLED CLINICAL-TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK
    BONE, RC
    FISHER, CJ
    CLEMMER, TP
    SLOTMAN, GJ
    METZ, CA
    BALK, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (11) : 653 - 658
  • [4] SEPSIS SYNDROME - A VALID CLINICAL ENTITY
    BONE, RC
    FISHER, CJ
    CLEMMER, TP
    SLOTMAN, GJ
    METZ, CA
    BALK, RA
    [J]. CRITICAL CARE MEDICINE, 1989, 17 (05) : 389 - 393
  • [5] LETS AGREE ON TERMINOLOGY - DEFINITIONS OF SEPSIS
    BONE, RC
    [J]. CRITICAL CARE MEDICINE, 1991, 19 (07) : 973 - 976
  • [6] DE M, 1992, DEV BIOL, V151, P297, DOI 10.1016/0012-1606(92)90234-8
  • [7] A CONTROLLED CLINICAL-TRIAL OF E5 MURINE MONOCLONAL IGM ANTIBODY TO ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS
    GREENMAN, RL
    SCHEIN, RMH
    MARTIN, MA
    WENZEL, RP
    MACINTYRE, NR
    EMMANUEL, G
    CHMEL, H
    KOHLER, RB
    MCCARTHY, M
    PLOUFFE, J
    RUSSELL, JA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (08): : 1097 - 1102
  • [8] BACTEREMIA AT BOSTON-CITY-HOSPITAL - OCCURRENCE AND MORTALITY DURING 12 SELECTED YEARS (1935-1972), WITH SPECIAL REFERENCE TO HOSPITAL-ACQUIRED CASES
    MCGOWAN, JE
    BARNES, MW
    FINLAND, M
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1975, 132 (03) : 316 - 335
  • [9] SEPTIC SHOCK AND MULTIPLE ORGAN FAILURE
    RUOKONEN, E
    TAKALA, J
    KARI, A
    ALHAVA, E
    [J]. CRITICAL CARE MEDICINE, 1991, 19 (09) : 1146 - 1151
  • [10] WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711